Results 131 to 140 of about 6,034,940 (339)

Regulatory Arrangements, Financial Stability and Regulatory Reform [PDF]

, 1995
What can be learned from the experience of the past decade or two about financial regulation, supervision, and deposit insurance or a financial safety net? Is there a better way to provide safety and soundness in the future than in the recent past? Does financial regulatory policy conflict with monetary policy?
openaire   +1 more source

Improving the implementation of regulation: time for a systemic approach [PDF]

, 2014
The importance of an ‘efficient and effective regulatory environment’ (Offices of the Ministers of Finance and Regulatory Reform, 2013) has never been more prominent in New Zealand than it is at the present time. The New Zealand Productivity Commission’s
Keith Manch
core   +1 more source

Organ‐specific redox imbalances in spinal muscular atrophy mice are partially rescued by SMN antisense oligonucleotides

FEBS Letters, EarlyView.
We identified a systemic, progressive loss of protein S‐glutathionylation—detected by nonreducing western blotting—alongside dysregulation of glutathione‐cycle enzymes in both neuronal and peripheral tissues of Taiwanese SMA mice. These alterations were partially rescued by SMN antisense oligonucleotide therapy, revealing persistent redox imbalance as ...
Sofia Vrettou, Brunhilde Wirth
wiley   +1 more source

Mystery machine: the complex roles of NLRX1 in viral infection

Frontiers in Immunology
Effective antiviral immunity requires a delicate balance between controlling infection and preventing excessive inflammation. NLRX1, an atypical member of the NOD-like receptor family, plays a crucial regulatory role in this process by modulating immune ...
Mackenzie K. Woolls, Carley M. Elliott, Hannah M. Ivester, Irving Coy Allen, Irving Coy Allen, Irving Coy Allen, Irving Coy Allen   +6 more
doaj   +1 more source

MicroRNAs: Target Recognition and Regulatory Functions

Cell, 2009
D. Bartel
semanticscholar   +1 more source

The Government’s Forward Regulatory Programme [PDF]

, 2010
Gives an overview of the Forward Programme, which identifies 308 regulatory changes that may be implemented between April 2010 up to and including April 2011 (comprising 265 new measures and 43 simplifications of existing measures).

core  

β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1

Molecular Oncology, EarlyView.
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero, Alejandro Belmonte‐Fernández, Mónica González‐Moreno, Laura Rodríguez‐Cordero, Begoña Pérez‐Valderrama, Joaquín Herrero‐Ruíz, Francisco Romero, Carmen Sáez, Miguel Á. Japón   +8 more
wiley   +1 more source

Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities.

Molecules and Cells, 2010
S. Heinz, C. Benner, N. Spann, E. Bertolino, Yin C Lin, P. Laslo, Jason X. Cheng, C. Murre, Harinder Singh, C. Glass   +9 more
semanticscholar   +1 more source

Nicotinamide N‐methyltransferase promotes drug resistance in lung cancer, as revealed by nascent proteomic profiling

Molecular Oncology, EarlyView.
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou, Zhen Wang, Fei Yang, Xiao Han, Lei Li, Huadong Liu   +5 more
wiley   +1 more source

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham, Jasibel Vasquez‐Gonzalez, Samantha M. Barnada, Salome Tchotorlishvili, Latese Jones, Ryan Maguire, Genevieve Lewis, Kinza Rizwan, Jenny Deng, Salma Koachar, Drithi Patel, Hailey Shankle, Tessa Mulders, Namra Ajmal, Charalambos Solomides, Emad S. Alnemri, Teresa F. Alnemri, Ayesha A. Shafi, Leonard G. Gomella, Wm Kevin Kelly, Steven B. McMahon, Matthew J. Schiewer   +21 more
wiley   +1 more source